advertisement
Biomedicines 30
Showing records 1 to 25 | Display only abstracts in Biomedicines from IGR 23-1107885 Clinical and Therapeutic Evaluation of the Ten Most Prevalent Mutations
Lopes da Costa B
Biomedicines 2023; 11: (IGR: 23-4)
107540 The Need for Glaucoma Management in Glaucoma Patients with Concurrent Obstructive Sleep Apnea: A Population-Based Cohort Study
Lee CY
Biomedicines 2023; 11: (IGR: 23-4)
107885 Clinical and Therapeutic Evaluation of the Ten Most Prevalent Mutations
Lopes da Costa B
Biomedicines 2023; 11: (IGR: 23-4)
108225 Novel Therapies for the Prevention of Fibrosis in Glaucoma Filtration Surgery
Shao CG
Biomedicines 2023; 11: (IGR: 23-4)
107885 Clinical and Therapeutic Evaluation of the Ten Most Prevalent Mutations
Kolesnikova M
Biomedicines 2023; 11: (IGR: 23-4)
108225 Novel Therapies for the Prevention of Fibrosis in Glaucoma Filtration Surgery
Sinha NR
Biomedicines 2023; 11: (IGR: 23-4)
107885 Clinical and Therapeutic Evaluation of the Ten Most Prevalent Mutations
Kolesnikova M
Biomedicines 2023; 11: (IGR: 23-4)
107540 The Need for Glaucoma Management in Glaucoma Patients with Concurrent Obstructive Sleep Apnea: A Population-Based Cohort Study
Chien HW
Biomedicines 2023; 11: (IGR: 23-4)
107885 Clinical and Therapeutic Evaluation of the Ten Most Prevalent Mutations
Levi SR
Biomedicines 2023; 11: (IGR: 23-4)
108225 Novel Therapies for the Prevention of Fibrosis in Glaucoma Filtration Surgery
Mohan RR
Biomedicines 2023; 11: (IGR: 23-4)
107540 The Need for Glaucoma Management in Glaucoma Patients with Concurrent Obstructive Sleep Apnea: A Population-Based Cohort Study
Huang JY; Yen CH
Biomedicines 2023; 11: (IGR: 23-4)
107885 Clinical and Therapeutic Evaluation of the Ten Most Prevalent Mutations
Cabral T
Biomedicines 2023; 11: (IGR: 23-4)
108225 Novel Therapies for the Prevention of Fibrosis in Glaucoma Filtration Surgery
Webel AD
Biomedicines 2023; 11: (IGR: 23-4)
107540 The Need for Glaucoma Management in Glaucoma Patients with Concurrent Obstructive Sleep Apnea: A Population-Based Cohort Study
Chen HC
Biomedicines 2023; 11: (IGR: 23-4)
107885 Clinical and Therapeutic Evaluation of the Ten Most Prevalent Mutations
Tsang SH; Maumenee IH
Biomedicines 2023; 11: (IGR: 23-4)
107540 The Need for Glaucoma Management in Glaucoma Patients with Concurrent Obstructive Sleep Apnea: A Population-Based Cohort Study
Hwang YS
Biomedicines 2023; 11: (IGR: 23-4)
107885 Clinical and Therapeutic Evaluation of the Ten Most Prevalent Mutations
Quinn PMJ
Biomedicines 2023; 11: (IGR: 23-4)
107540 The Need for Glaucoma Management in Glaucoma Patients with Concurrent Obstructive Sleep Apnea: A Population-Based Cohort Study
Chang CK
Biomedicines 2023; 11: (IGR: 23-4)
107885 Clinical and Therapeutic Evaluation of the Ten Most Prevalent Mutations
Quinn PMJ; Quinn PMJ
Biomedicines 2023; 11: (IGR: 23-4)
107540 The Need for Glaucoma Management in Glaucoma Patients with Concurrent Obstructive Sleep Apnea: A Population-Based Cohort Study
Yang SF
Biomedicines 2023; 11: (IGR: 23-4)
106865 Gamma-Synuclein Dysfunction Causes Autoantibody Formation in Glaucoma Patients and Dysregulation of Intraocular Pressure in Mice
Pavlenko TA; Roman AY; Lytkina OA; Pukaeva NE; Everett MW; Sukhanova IS; Soldatov VO; Davidova NG; Chesnokova NB; Ovchinnikov RK; Kukharsky MS
Biomedicines 2022; 11: (IGR: 23-3)
104426 Widen the Applicability of a Convolutional Neural-Network-Assisted Glaucoma Detection Algorithm of Limited Training Images across Different Datasets
Ko YC; Chen WS; Chen HH; Hsu TK; Chen YC; Liu CJ; Lu HH
Biomedicines 2022; 10: (IGR: 23-2)
100729 Retinal Changes in Astrocytes and Müller Glia in a Mouse Model of Laser-Induced Glaucoma: A Time-Course Study
Fernández-Albarral JA; de Hoz R; Matamoros JA; Chen L; López-Cuenca I; Salobrar-García E; Sánchez-Puebla L; Ramírez JM; Triviño A; Salazar JJ; Ramírez AI
Biomedicines 2022; 10: (IGR: 23-1)
99228 Cardiac Hypertrophy May Be a Risk Factor for the Development and Severity of Glaucoma
Suzuki Y
Biomedicines 2022; 10: (IGR: 22-4)
99227 Early-Onset Glaucoma in Mice Homozygous for Mutation
Kodati B; Merchant SA
Biomedicines 2022; 10: (IGR: 22-4)